Advertisement
Screener

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) Interest Expense Nonoperating

2.8 / 5 stars · 68/120 Roast Me

INTEGRA LIFESCIENCES HOLDINGS CORP Interest Expense Nonoperating

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) reported Interest Expense Nonoperating of $22.99 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Expense Statement

us-gaap:InterestExpenseNonoperating · last filed 2026-07-29

  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for the quarter ending 2026-06-30 was $22.99M, a 9.28% increase year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for the quarter ending 2026-03-31 was $22.46M, a 19.40% increase year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for the quarter ending 2025-12-31 was $23.67M, a 24.70% increase year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for the quarter ending 2025-09-30 was $22.73M, a 17.30% increase year-over-year.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for fiscal 2025 was $86.25M, a 22.12% increase from fiscal 2024.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for fiscal 2024 was $70.63M, a 37.48% increase from fiscal 2023.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for fiscal 2023 was $51.38M, a 3.60% increase from fiscal 2022.
  • INTEGRA LIFESCIENCES HOLDINGS CORP interest expense nonoperating for fiscal 2022 was $49.59M.
Period endInterest Expense Nonoperating 3 monthInterest Expense Nonoperating 6 monthInterest Expense Nonoperating 9 monthInterest Expense Nonoperating 12 month
2026-06-30$22.99M
10-Q · filed 2026-07-29
$45.46M
10-Q · filed 2026-07-29
$69.13M
derived: sum of 3 quarters · filed 2026-07-29
$91.86M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$22.46M
10-Q · filed 2026-05-05
$46.14M
derived: sum of 2 quarters · filed 2026-05-05
$68.86M
derived: sum of 3 quarters · filed 2026-05-05
$89.91M
derived: sum of 4 quarters · filed 2026-07-29
2025-12-31$23.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$46.40M
derived: sum of 2 quarters · filed 2026-02-26
$67.44M
derived: sum of 3 quarters · filed 2026-07-29
$86.25M
10-K · filed 2026-02-26
2025-09-30$22.73M
10-Q · filed 2025-10-30
$43.77M
derived: sum of 2 quarters · filed 2026-07-29
$62.58M
10-Q · filed 2025-10-30
$81.57M
derived: sum of 4 quarters · filed 2026-07-29
2025-06-30$21.04M
10-Q · filed 2026-07-29
$39.86M
10-Q · filed 2026-07-29
$58.84M
derived: sum of 3 quarters · filed 2026-07-29
$78.21M
derived: sum of 4 quarters · filed 2026-07-29
2025-03-31$18.82M
10-Q · filed 2026-05-05
$37.80M
derived: sum of 2 quarters · filed 2026-05-05
$57.17M
derived: sum of 3 quarters · filed 2026-05-05
$75.82M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$18.98M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$38.36M
derived: sum of 2 quarters · filed 2026-02-26
$57.01M
derived: sum of 3 quarters · filed 2026-02-26
$70.63M
10-K · filed 2026-02-26
2024-09-30$19.37M
10-Q · filed 2025-10-30
$38.02M
derived: sum of 2 quarters · filed 2025-10-30
$51.65M
10-Q · filed 2025-10-30
$65.40M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$18.65M
10-Q · filed 2025-07-31
$32.27M
10-Q · filed 2025-07-31
$46.03M
derived: sum of 3 quarters · filed 2026-02-26
$59.09M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$13.62M
10-Q · filed 2025-05-05
$27.38M
derived: sum of 2 quarters · filed 2026-02-26
$40.44M
derived: sum of 3 quarters · filed 2026-02-26
$52.90M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$13.75M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$26.81M
derived: sum of 2 quarters · filed 2026-02-26
$39.28M
derived: sum of 3 quarters · filed 2026-02-26
$51.38M
10-K · filed 2026-02-26
2023-09-30$13.06M
10-Q · filed 2024-11-04
$25.53M
derived: sum of 2 quarters · filed 2024-11-04
$37.63M
10-Q · filed 2024-11-04
2023-06-30$12.46M
10-Q · filed 2024-07-29
$24.56M
10-Q · filed 2024-07-29
2022-12-31$49.59M
10-K · filed 2025-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77
Beta Bionics, Inc. (BBNX)United States$0.979B-9.66
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
SpyGlass Pharma, Inc. (SGP)United States$0.925B
SI-BONE, Inc. (SIBN)United States$0.830B-49.82
MIMEDX GROUP, INC. (MDXG)United States$0.687B89.92